Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn's Disease.

ABSTRACT:

Background

Therapeutic drug monitoring of adalimumab (ADA) is still controversial.

Objectives

To study the association between ADA trough levels in the early stages of treatment with biological remission (BR) and drug survival in Crohn's disease (CD).

Design

Retrospective cohort study.

Methods

Patients treated with ADA with available trough levels at weeks 2 and 6 (after the first induction and maintenance dose, respectively) were included. Fecal calprotectin (Fcal) and C-reactive protein (CRP) were registered at baseline, week 24, and week 52. BR was defined as Fcal <200 µg/g and CRP <5 mg/dl. Treatment survival and the need for dose escalation were assessed at week 52. Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic ac

SUBMITTER: Rueda Garcia JL 

PROVIDER: S-EPMC11921000 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature